Millennium Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Millennium Management’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$562K	Sell	564,600 -37,000	-6%	-$44K	﹤0.01%	4705
2025 Q4	$818K	Sell	601,600 -23,097	-4%	-$33.7K	﹤0.01%	4622
2025 Q3	$1,000K	Sell	624,697 -38,572	-6%	-$62.8K	﹤0.01%	4629
2025 Q2	$929K	Buy	+663,269	New	+$993K	﹤0.01%	4466
2025 Q1	–	Sell	-117,454	Closed	-$148K	–	5836
2024 Q4	$148K	Sell	117,454 -42,669	-27%	-$66.2K	﹤0.01%	5393
2024 Q3	$301K	Buy	160,123 +139,085	+661%	+$550K	﹤0.01%	5184
2024 Q2	$156K	Sell	21,038 -46,373	-69%	-$382K	﹤0.01%	5224
2024 Q1	$528K	Buy	+67,411	New	+$433K	﹤0.01%	4771
2023 Q2	–	Sell	-231,172	Closed	-$2.19M	–	6093
2023 Q1	$2.19M	Buy	231,172 +177,392	+330%	+$1.87M	﹤0.01%	3359
2022 Q4	$573K	Buy	53,780 +4,632	+9%	+$47K	﹤0.01%	4642
2022 Q3	$363K	Buy	49,148 +16,008	+48%	+$99.5K	﹤0.01%	5220
2022 Q2	$159K	Buy	+33,140	New	+$188K	﹤0.01%	5746
2021 Q1	–	Sell	-55,020	Closed	-$429K	–	5891
2020 Q4	$429K	Buy	+55,020	New	+$598K	﹤0.01%	4316
2019 Q3	–	Sell	-509	Closed	-$4K	–	4143
2019 Q2	$4K	Buy	+509	New	+$5.11K	﹤0.01%	3988
2018 Q4	–	Sell	-540	Closed	-$12K	–	3734
2018 Q3	$12K	Sell	540 -579	-52%	-$11.8K	﹤0.01%	3837
2018 Q2	$21K	Sell	1,119 -4,349	-80%	-$55.1K	﹤0.01%	3732
2018 Q1	$60K	Buy	+5,468	New	+$92.9K	﹤0.01%	3523
2015 Q4	–	Sell	-5,501	Closed	-$292K	–	3403
2015 Q3	$292K	Buy	5,501 +75	+1%	+$5.01K	﹤0.01%	2926
2015 Q2	$431K	Buy	+5,426	New	+$463K	﹤0.01%	2705

Other funds holding ATNM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management's ATNM Position: Q1 2026 in Review

Millennium Management reduced its Actinium Pharmaceuticals (ATNM) stake by 6.2% in Q1 2026, selling an estimated $44K and leaving 564,600 shares worth $562K. The position accounts for ﹤0.01% of the portfolio, ranked #4705.

Millennium Management first reported a position in ATNM in Q2 2015 and has held it in 19 quarters since. The position peaked at $2.19M in Q1 2023. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

Millennium Management held 564,600 shares of Actinium Pharmaceuticals worth $562K as of Q1 2026.
Millennium Management sold 37,000 Actinium Pharmaceuticals shares in Q1 2026, an estimated $44K.
Actinium Pharmaceuticals made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4705 holding.
Millennium Management first reported a position in Actinium Pharmaceuticals in Q2 2015 and has held it in 19 quarters since.
Millennium Management's Actinium Pharmaceuticals position peaked at $2.19M in Q1 2023.
54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.